Data / Drug companies / Brivaracetam
Brivaracetam: 17 companies and 60 products in the FDA NDC directory
Brivaracetam is listed in the FDA National Drug Code Directory by 17 companies, with 60 products in commercial distribution. 53 of the products (88.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; solution; tablet, and the newest product started marketing on August 10, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 17
- Products
- 60
- Generic (ANDA) products
- 53 (88.3%)
- Application numbers
- 17
- Controlled substance schedule
- Schedule V
- Routes
- Oral, Intravenous
- Brand names
- Briviact
- openFDA record search
- api.fda.gov
Companies that list brivaracetam
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Novadoz Pharmaceuticals LLC | 7 | tablet, film coated; solution | Generic drugs (ANDA) | February 23, 2026 |
| Ucb, Inc. | 7 | tablet, film coated; solution | New drug applications (NDA) | May 12, 2016 |
| Apotex Corp. | 5 | tablet | Generic drugs (ANDA) | February 24, 2026 |
| Aurobindo Pharma Limited | 5 | tablet, film coated | Generic drugs (ANDA) | July 13, 2026 |
| Exelan Pharmaceuticals Inc. | 5 | tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| ScieGen Pharmaceuticals, Inc. | 5 | tablet, film coated | Generic drugs (ANDA) | March 27, 2026 |
| Solaris Pharma Corporation | 5 | tablet, film coated | Generic drugs (ANDA) | February 4, 2026 |
| Zydus Lifesciences Limited | 5 | tablet, film coated | Generic drugs (ANDA) | February 21, 2026 |
| Zydus Pharmaceuticals USA Inc. | 5 | tablet, film coated | Generic drugs (ANDA) | February 21, 2026 |
| AvKARE | 4 | tablet, film coated | Generic drugs (ANDA) | May 5, 2026 |
| Ascend Laboratories, LLC | 1 | solution | Generic drugs (ANDA) | February 23, 2026 |
| Aurobindo Pharma Limited | 1 | solution | Generic drugs (ANDA) | August 10, 2026 |
| Hainan Poly Pharm. Co., Ltd. | 1 | injection | Generic drugs (ANDA) | February 21, 2026 |
| Lupin Pharmaceuticals, Inc. | 1 | solution | Generic drugs (ANDA) | February 23, 2026 |
| Micro Labs Limited | 1 | injection | Generic drugs (ANDA) | March 1, 2026 |
| Pai Holdings, LLC DBA Pai Pharma | 1 | solution | Generic drugs (ANDA) | February 23, 2026 |
| Zhejiang Poly Pharm. Co., Ltd. | 1 | solution | Generic drugs (ANDA) | February 21, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 44 | 73.3% |
| Solution | 7 | 11.7% |
| Tablet | 5 | 8.3% |
| Injection | 2 | 3.3% |
| Injection, suspension | 1 | 1.7% |
| Injection, solution | 1 | 1.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 53 | 88.3% |
| New drug applications (NDA) | 7 | 11.7% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.